<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247220</url>
  </required_header>
  <id_info>
    <org_study_id>20101717</org_study_id>
    <nct_id>NCT01247220</nct_id>
  </id_info>
  <brief_title>REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study</brief_title>
  <acronym>Revolution</acronym>
  <official_title>REVOLUTIONARY: REtinal Vein OccLUsion Treatment With Scatter Laser Guided by Ultra Widefield angIOgraphy in combiNAtion With Ranibizumab Study Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Associates of Florida, P.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Retina Associates of Florida, P.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Branch retinal vein occlusion is a leading cause of vision loss. Treatment with ranibizumab&#xD;
      (vascular endothelial growth factor (VEGF) inhibitor) on a monthly basis has been associated&#xD;
      with improved vision results. There is a subgroup of patients with peripheral nonperfusion on&#xD;
      ultrawidefield angiography that appears to be more dependent on anti-VEGF treatment.&#xD;
&#xD;
      In this trial the investigators compare the gold standard of monthly ranibizumab injections&#xD;
      with ranibizumab + peripheral scatter laser to the areas of nonperfusion on angiography. Each&#xD;
      group will have monthly injections for the first six months, then as needed by either visual&#xD;
      acuity decrease or increased retinal thickness for the subsequent six months.&#xD;
&#xD;
      The primary outcome is visual acuity. Secondary outcomes are reduction in optical coherence&#xD;
      tomography, and number of ranibizumab injections&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SUBJECTS Subject Selection Twenty subjects from a single site in the United States will be&#xD;
      enrolled. Eligible subjects will have provided informed consent. (See Appendix A, the study&#xD;
      flow chart, for screening assessments.)&#xD;
&#xD;
      Inclusion Criteria&#xD;
&#xD;
      Subjects will be eligible if the following criteria are met:&#xD;
&#xD;
      Ability to provide written informed consent and comply with study assessments for the full&#xD;
      duration of the study Age &gt; 18 years&#xD;
&#xD;
      Disease related considerations:&#xD;
&#xD;
      Study eye with macular edema secondary to branch retinal vein occlusion characterized by:&#xD;
&#xD;
      Fovea-involved macular edema of less than 12 months peripheral nonperfusion defined as at&#xD;
      least 5 disc areas of contiguous nonperfusion on ultra-widefield fluorescein angiography&#xD;
      absence of macular traction on clinical exam, UWFA, and OCT.&#xD;
&#xD;
      Study eye with best corrected visual acuity between 20/40 (≤ 73 letters on ETDRS chart) and&#xD;
      20/320 (≥ 19 letters on ETDRS chart) Other considerations Patient able to complete all study&#xD;
      visits&#xD;
&#xD;
      Exclusion Criteria&#xD;
&#xD;
      Subjects who meet any of the following criteria will be excluded from this study:&#xD;
&#xD;
      Pregnancy (positive pregnancy test) or lactation. Premenopausal women not using adequate&#xD;
      contraception. The following are considered effective means of contraception: surgical&#xD;
      sterilization or use of oral contraceptives, barrier contraception with either a condom or&#xD;
      diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or&#xD;
      patch.&#xD;
&#xD;
      Prior enrollment in the study Any other condition that the investigator believes would pose a&#xD;
      significant hazard to the subject if the investigational therapy were initiated Participation&#xD;
      in another simultaneous medical investigation or trial Therapy with intravitreal&#xD;
      triamcinolone, pegaptanib, ranibizumab, or bevacizumab within the previous 3 months Previous&#xD;
      macular or panretinal scatter laser photocoagulation Previous pars plana vitrectomy&#xD;
      Visually-significant significant cataracts as primary reason for vision loss Myocardial&#xD;
      infarction or cerebrovascular accident within 6 months&#xD;
&#xD;
      METHOD OF TREATMENT ASSIGNMENT Patients meeting the study criteria and providing informed&#xD;
      consent will be randomized according to the attached randomization chart (Appendix E) to&#xD;
      study or control arm until 10 eyes are assigned to each group. Patients with both eyes&#xD;
      eligible for the study will be assigned by coin flip.&#xD;
&#xD;
      STUDY TREATMENT Formulation Ranibizumab is formulated as a sterile solution aseptically&#xD;
      filled in a sterile, 2 mL or 3-mL stoppered glass vial. Each single use vial is designed to&#xD;
      deliver 0.05 mL of 10 mg/mL ranibizumab aqueous solution with 10 mM histidine HCI, 10%,&#xD;
      trehalose dihydrate, and 0.01% polysorbate 20, pH 5.5. Each vial contains no preservative and&#xD;
      is suitable for single use only.&#xD;
&#xD;
      Further details and molecule characterization will be included in the Investigator Brochure.&#xD;
&#xD;
      Dosage, Administration, and Storage&#xD;
&#xD;
        1. Dosage Patients in the treatment and control arms will receive intravitreal injection of&#xD;
           0.5 mg ranibizumab on the screening/Day 0 visit, and months 1 - 5. The need for&#xD;
           subsequent injections at months 6 - 11 will be determined by presence of persistent or&#xD;
           recurrent intraretinal fluid on OCT evaluation.&#xD;
&#xD;
        2. Administration&#xD;
&#xD;
        3. Storage Upon receipt, study drug kits should be refrigerated at 2C - 8C (36F - 46F). DO&#xD;
           NOT FREEZE. Do not use beyond the expiration date. Ranibizumab vials should remain&#xD;
           refrigerated. Protect vials from direct sunlight. Store in original carton until time of&#xD;
           use.&#xD;
&#xD;
           RANIBIZUMAB VIALS ARE FOR SINGLE USE ONLY. Vials used for one subject may not be used&#xD;
           for any other subject.&#xD;
&#xD;
           CONCOMITANT AND EXCLUDED THERAPIES Subjects may continue to receive all medications and&#xD;
           standard treatments administered for their conditions at the discretion of their&#xD;
           treating physician.&#xD;
&#xD;
           STUDY ASSESSMENTS Assessments during the Treatment Period Screening / Day 0 Visit&#xD;
           Informed consent Demographic data Medical and ocular history Vital signs (BP, heart&#xD;
           rate) Pregnancy test (if applicable) Best corrected visual acuity (BCVA) ETDRS chart&#xD;
           Slit lamp examination Intraocular pressure Dilated fundus examination Optical Coherence&#xD;
           Tomography UWFA Ranibizumab treatment + peripheral laser tx (Treatment group)&#xD;
           Ranibizumab treatment (Comparative group) SAE Monitoring Post-injection Phone Follow-up&#xD;
           Update medical and ocular history SAE Monitoring Months 1, 2, 3, 4, and 5 Visits Update&#xD;
           medical and ocular history Vital signs Best corrected visual acuity (BCVA) ETDRS chart&#xD;
           Slit lamp examination Intraocular pressure Dilated fundus examination UWFA (Month 3)&#xD;
           Ranibizumab treatment (Treatment and Comparative group) Optical Coherence Tomography SAE&#xD;
           monitoring Month 6 Visit Update medical and ocular history Vital signs Best corrected&#xD;
           visual acuity (BCVA) ETDRS chart Slit lamp examination Intraocular pressure Dilated&#xD;
           fundus examination Optical Coherence Tomography UWFA SAE monitoring Months 6, 7, 8, 9,&#xD;
           10, 11, and 12 Visits Update medical and ocular history Vital signs Best corrected&#xD;
           visual acuity (BCVA) ETDRS chart Slit lamp examination Intraocular pressure Dilated&#xD;
           fundus examination Optical Coherence Tomography Ranibizumab treatment if necessary as&#xD;
           determined by Optical Coherence Tomography assessment (Treatment and Comparative group)&#xD;
           SAE monitoring&#xD;
&#xD;
           Early Termination Assessments Subjects who withdraw from the study prior to completion&#xD;
           should return for an early termination evaluation 30 days (14 days) following the last&#xD;
           injection/study visit for monitoring of all adverse events (serious and nonserious). The&#xD;
           schedule of assessments for early termination is the same as that for the final visit.&#xD;
&#xD;
           SUBJECT DISCONTINUATION Subjects have a right to withdraw from the study at any time.&#xD;
           The subject may be withdrawn from the study for any reasons: if it is in the best&#xD;
           interest of the subject, intercurrent illness, adverse events, or worsening condition.&#xD;
           The Western IRB may request the withdrawal of a subject because of protocol violations,&#xD;
           administrative reasons, or any other valid and ethical reasons.&#xD;
&#xD;
           If a subject discontinues from the study, he or she will not be allowed to re enter the&#xD;
           study.&#xD;
&#xD;
           Reasons for subject discontinuation may include, but are not limited to, the following:&#xD;
&#xD;
           Sensory rhegmatogenous retinal detachment or Stage 3 or 4 macular hole Investigator&#xD;
           determination that it is not in the best interest of the subject to continue&#xD;
           participation Pregnancy Verteporfin PDT treatment in the study eye Pegaptanib sodium&#xD;
           injection treatment in either eye Bevacizumab injection in either eye SAE Any other&#xD;
           safety concerns In the event of an adverse event in the study eye that is considered by&#xD;
           the investigator to be severe in intensity, serious consideration should be given to&#xD;
           discontinuing the subject from the study.&#xD;
&#xD;
           STUDY DISCONTINUATION&#xD;
&#xD;
           This study may be terminated by Western IRB or Retina Associates of Florida at any time.&#xD;
           Reasons for terminating the study may include the following:&#xD;
&#xD;
           The incidence or severity of adverse events in this or other studies indicates a&#xD;
           potential health hazard to subjects Subject enrollment is unsatisfactory Data recording&#xD;
           is inaccurate or incomplete&#xD;
&#xD;
           STATISTICAL METHODS Analysis of the Conduct of the Study There is no formal sample size&#xD;
           calculation in this pilot study. As this is a phase I study, a sample size of 30&#xD;
           patients is chosen, making sure that it is feasible financially to conduct the study and&#xD;
           logistically to complete the study within 18 months. If and when the study is planned&#xD;
           for a phase II randomized control trial, appropriate statistical analysis will be&#xD;
           determined.&#xD;
&#xD;
           Safety Analyses Any adverse events, laboratory assessments, physical examinations, vital&#xD;
           signs, ocular examinations and measurements from all 30 subjects will be utilized to&#xD;
           summarize safety data for this pilot study.&#xD;
&#xD;
           Efficacy Analyses Primary Endpoint Mean change in best corrected visual acuity (BCVA),&#xD;
           as assessed by the number of letters read correctly on the ETDRS eye chart at a starting&#xD;
           test distance of 4 meters at Month 6. This will also include eyes with gain of 15&#xD;
           letters or more, or loss of 15 letters or more on the ETDRS eye chart Secondary&#xD;
           Endpoints Mean change in best corrected visual acuity (BCVA), as assessed by the number&#xD;
           of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters&#xD;
           at Month 2.&#xD;
&#xD;
           Percent reduction of foveal thickness by optical coherence tomography. Percent reduction&#xD;
           of macular volume by optical coherence tomography. Mean number of injections between&#xD;
           Months 6 and 12.&#xD;
&#xD;
           Missing Data Analyses of efficacy and safety will be based on available cases, without&#xD;
           imputation for missing values.&#xD;
&#xD;
           Interim Analyses No formal schedule of interim analyses is planned. Reports of adverse&#xD;
           events from this study may be reviewed and summarized periodically while the study is&#xD;
           ongoing to ensure the safety of subjects.&#xD;
&#xD;
           DATA QUALITY ASSURANCE Accurate, consistent, and reliable data will be ensured through&#xD;
           the use of standard practices and procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>ETDRS visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Ranibizumab Injections</measure>
    <time_frame>12 months</time_frame>
    <description>Number of ranibizumab injections needed by decreased visual acuity and/or increasing retinal thickness in second six months of observation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>central foveal thickness on optical coherence tomography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Macular Edema</condition>
  <condition>Branch Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Peripheral Laser + Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Angiography-directed peripheral laser + ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Intravitreal Ranibizumab 0.5 mg</description>
    <arm_group_label>Peripheral Laser + Ranibizumab</arm_group_label>
    <arm_group_label>Ranibizumab</arm_group_label>
    <other_name>Standard of Care</other_name>
    <other_name>Intravitreal Anti-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Laser</intervention_name>
    <description>Angiography-directed peripheral laser</description>
    <arm_group_label>Peripheral Laser + Ranibizumab</arm_group_label>
    <other_name>Experimental</other_name>
    <other_name>Scatter Laser</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects will be eligible if the following criteria are met:&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with study assessments for the&#xD;
             full duration of the study&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
               -  Disease related considerations:&#xD;
&#xD;
               -  Study eye with macular edema secondary to branch retinal vein occlusion&#xD;
                  characterized by:&#xD;
&#xD;
          -  Fovea-involved macular edema of less than 12 months peripheral nonperfusion defined as&#xD;
             at least 5 disc areas of contiguous nonperfusion on ultra-widefield fluorescein&#xD;
             angiography absence of macular traction on clinical exam, UWFA, and OCT.&#xD;
&#xD;
          -  Study eye with best corrected visual acuity between 20/40 (≤ 73 letters on ETDRS&#xD;
             chart) and 20/320 (≥ 19 letters on ETDRS chart)&#xD;
&#xD;
          -  Other considerations&#xD;
&#xD;
          -  Patient able to complete all study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who meet any of the following criteria will be excluded from this study:&#xD;
&#xD;
               -  Pregnancy (positive pregnancy test) or lactation. Premenopausal women not using&#xD;
                  adequate contraception. The following are considered effective means of&#xD;
                  contraception: surgical sterilization or use of oral contraceptives, barrier&#xD;
                  contraception with either a condom or diaphragm in conjunction with spermicidal&#xD;
                  gel, an IUD, or contraceptive hormone implant or patch.&#xD;
&#xD;
               -  Prior enrollment in the study&#xD;
&#xD;
               -  Any other condition that the investigator believes would pose a significant&#xD;
                  hazard to the subject if the investigational therapy were initiated&#xD;
&#xD;
               -  Participation in another simultaneous medical investigation or trial&#xD;
&#xD;
               -  Therapy with intravitreal triamcinolone, pegaptanib, ranibizumab, or bevacizumab&#xD;
                  within the previous 3 months&#xD;
&#xD;
               -  Previous macular or panretinal scatter laser photocoagulation&#xD;
&#xD;
               -  Previous pars plana vitrectomy&#xD;
&#xD;
               -  Visually-significant significant cataracts as primary reason for vision loss&#xD;
&#xD;
               -  Myocardial infarction or cerebrovascular accident within 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan J Suner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Retina Associates of Florida, P.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Associates of Florida, P.A.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <results_first_submitted>October 1, 2014</results_first_submitted>
  <results_first_submitted_qc>October 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2014</results_first_posted>
  <last_update_submitted>October 3, 2014</last_update_submitted>
  <last_update_submitted_qc>October 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Retina Associates of Florida, P.A.</investigator_affiliation>
    <investigator_full_name>Ivan J. Suner, MD</investigator_full_name>
    <investigator_title>Director of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>Macular Edema</keyword>
  <keyword>Branch retinal vein occlusion</keyword>
  <keyword>Ranibizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Peripheral Laser + Ranibizumab</title>
          <description>Angiography-directed peripheral laser + ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg&#xD;
Peripheral Laser: Angiography-directed peripheral laser</description>
        </group>
        <group group_id="P2">
          <title>Ranibizumab</title>
          <description>Ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peripheral Laser + Ranibizumab</title>
          <description>Angiography-directed peripheral laser + ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg&#xD;
Peripheral Laser: Angiography-directed peripheral laser</description>
        </group>
        <group group_id="B2">
          <title>Ranibizumab</title>
          <description>Ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="18"/>
                    <measurement group_id="B2" value="70" spread="10"/>
                    <measurement group_id="B3" value="69.5" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity</title>
        <description>ETDRS visual acuity</description>
        <time_frame>6 and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peripheral Laser + Ranibizumab</title>
            <description>Angiography-directed peripheral laser + ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg&#xD;
Peripheral Laser: Angiography-directed peripheral laser</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab</title>
            <description>Ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>ETDRS visual acuity</description>
          <units>letters on ETDRS Visual Acuity Chart</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 month results</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="10.1"/>
                    <measurement group_id="O2" value="14.5" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month results</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="7.4"/>
                    <measurement group_id="O2" value="15.3" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Ranibizumab Injections</title>
        <description>Number of ranibizumab injections needed by decreased visual acuity and/or increasing retinal thickness in second six months of observation period</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peripheral Laser + Ranibizumab</title>
            <description>Angiography-directed peripheral laser + ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg&#xD;
Peripheral Laser: Angiography-directed peripheral laser</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab</title>
            <description>Ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Ranibizumab Injections</title>
          <description>Number of ranibizumab injections needed by decreased visual acuity and/or increasing retinal thickness in second six months of observation period</description>
          <units>injections</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinal Thickness</title>
        <description>central foveal thickness on optical coherence tomography</description>
        <time_frame>6 and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peripheral Laser + Ranibizumab</title>
            <description>Angiography-directed peripheral laser + ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg&#xD;
Peripheral Laser: Angiography-directed peripheral laser</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab</title>
            <description>Ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Retinal Thickness</title>
          <description>central foveal thickness on optical coherence tomography</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 month results</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207" spread="47"/>
                    <measurement group_id="O2" value="241" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month results</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282" spread="26"/>
                    <measurement group_id="O2" value="281" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Peripheral Laser + Ranibizumab</title>
          <description>Angiography-directed peripheral laser + ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg&#xD;
Peripheral Laser: Angiography-directed peripheral laser</description>
        </group>
        <group group_id="E2">
          <title>Ranibizumab</title>
          <description>Ranibizumab&#xD;
Ranibizumab: Intravitreal Ranibizumab 0.5 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small study size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ivan J. Suner, MD</name_or_title>
      <organization>Retina Associates of Florida</organization>
      <phone>813-875-6373</phone>
      <email>ivansuner@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

